Cerecin
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Founded Year
2001Stage
Series H - II | AliveTotal Raised
$287.9MLast Raised
$30M | 1 yr agoAbout Cerecin
Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment.
Cerecin Headquarter Location
8 Shenton Way #08-02, AXA Tower
068811,
Singapore
+65 6813 2999
Expert Collections containing Cerecin
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cerecin is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Cerecin Patents
Cerecin has filed 14 patents.
The 3 most popular patent topics include:
- Metabolism
- Antiseptics
- Fatty acids
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/21/2017 | 10/30/2018 | Transcription factors, Diabetes, Alzheimer's disease, Metabolism, Rare diseases | Grant |
Application Date | 3/21/2017 |
|---|---|
Grant Date | 10/30/2018 |
Title | |
Related Topics | Transcription factors, Diabetes, Alzheimer's disease, Metabolism, Rare diseases |
Status | Grant |
Latest Cerecin News
Oct 26, 2021
Oct. 26, 2021 Cerecin Inc. has raised $40 million in an oversubscribed round of financing, paving the way for a potential listing in South Korea. Proceeds of the financing will fund the expansion of the company’s current studies and support the planning and initiation of a global phase III study of its lead candidate, tricaprilin, in Alzheimer’s disease.
Cerecin Web Traffic
Cerecin Rank
When was Cerecin founded?
Cerecin was founded in 2001.
What is Cerecin's latest funding round?
Cerecin's latest funding round is Series H - II.
How much did Cerecin raise?
Cerecin raised a total of $287.9M.
Who are the investors of Cerecin?
Investors of Cerecin include Inventages Venture Capital, Shinhan Investment Corp., Hana Financial Investment, K&T Capital, SK Securities and 12 more.
Who are Cerecin's competitors?
Competitors of Cerecin include Oligomerix, Longevica, MaxCyte, Array Biopharma, AngioChem, Irvine Pharmaceutical Services, BIND Therapeutics, Probiodrug, Limerick BioPharma, ZymoGenetics and 14 more.
You May Also Like
AngioChem is a clinical-stage biotechnology discovering and developing drugs that are capable of crossing the blood-brain barrier to treat brain diseases. The company's EPiC platform aims to solve the key problem for crossing the blood-brain barrier by developing drugs that use a receptor-based approach.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.
Serentis is a biopharmaceutical company which aims to develop a pipeline of products to address unmet medical needs in the dermatology field. The company's strategy is to establish a clinical stage development pipeline by the reprofiling of existing drugs and through the licensing or acquisition of projects from external sources. This is an approach that Serentis' management team has successfully pursued in the past.
Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.
Edunn Biotechnology, Inc. is developing oligonucleotide drugs to treat central nervous system diseases. The company currently has two drugs in development. Edunn's OL-1 drug is designed to cure Alzheimer's disease and to treat Down syndrome. Per the company, it is highly selective and has shown significant activity and safety in multiple preclinical models. The company's OL-202 would be used to treat stroke and traumatic brain injury.
Oxurion is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in-house expertise and collaborations with academic institutions to build a strong pipeline of promising drug candidates in cardiovascular diseases, visual disorders, and cancer.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.